Clinical Trial Update: Dapagliflozin Effect on Cardiovascular Outcomes in Haemodialysis for End Stage Renal Disease [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial evaluating dapagliflozin for cardiovascular outcomes in patients on haemodialysis with end-stage renal disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Diseases
• End-stage Renal Disease

Drugs mentioned

• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: Tan Tock Seng Hospital | Conditions: Cardiovascular Diseases, End Stage Renal Disease | Phase 2, Phase 3 | Status: WITHDRAWN